Cipla Q2 hit by seasonal chill, but investors need not worry

Cipla's September-quarter performance saw a 5.6% increase in consolidated net sales and a 15% rise in net profit despite slow seasonal growth in the anti-infectives category. The company expects a resurgence in growth due to seasonal respiratory illnesses and plans to address supply challenges and facility remediations in upcoming quarters.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uPDmSRM
via IFTTT